PKA Kinase Activity Kit (ab139435) is a non-radioactive assay providing a safe, rapid and reliable method for the screening of inhibitors or activators of PKA and for quantitating the activity of PKA in purified or partially purified enzyme preparations.
PKA Kinase Activity Kit (ab139435) is a non-radioactive assay providing a safe, rapid and reliable method for the screening of inhibitors or activators of PKA and for quantitating the activity of PKA in purified or partially purified enzyme preparations.
Sample | n | mean | SD | C.V. |
---|---|---|---|---|
Sample Sample | n 0 | mean - | SD - | C.V. < 10 |
Sample | n | mean | SD | C.V. |
---|---|---|---|---|
Sample Sample | n 0 | mean - | SD - | C.V. <= 12 |
PKA Kinase Activity Kit (ab139435) is a non-radioactive assay providing a safe, rapid and reliable method for the screening of inhibitors or activators of PKA and for quantitating the activity of PKA in purified or partially purified enzyme preparations. This kit is based on a solid phase enzyme-linked immuno-absorbent assay (ELISA) that utilizes a specific synthetic peptide as a substrate for PKA and a polyclonal antibody that recognizes the phosphorylated form of the substrate. The assay is designed for the analysis of PKA activity in the solution phase. This kit gives you the ability to an end-point or kinetic assay read-out in a convenient 96-well plate based assay and offers easy sample handling protocols.
The kit offers the following advantages:
1. Safe - non-radioactive measurement of kinase activity
2. Flexible - kinetic and end-point options available
3. Fast - results in < 4.5 hours
4. Efficient - only 30 μl diluted sample needed per well
Protein kinase A (PKA) also known as cAMP-dependent protein kinase plays an important role in cellular signaling. It is composed of a regulatory and a catalytic subunit having a molecular mass around 150 kDa. PKA is expressed widely in tissues such as the heart brain and skeletal muscle. The activation of PKA occurs when cyclic adenosine monophosphate (cAMP) binds to its regulatory subunit leading to the release of the catalytic subunit which then phosphorylates various target proteins.
PKA acts as a significant regulator of gene expression and cellular metabolism. It functions within the PKA signaling complex which includes A-kinase anchoring proteins (AKAPs) that localize PKA to specific areas in the cell aiding in precise function. PKA modulates processes such as lipolysis glycogen metabolism and transcription. Through these activities it contributes to cellular responses to hormonal changes by phosphorylating key substrates.
PKA activation integrates into the cAMP signaling pathway an essential regulatory pathway influencing a broad range of physiological responses. This pathway connects PKA with the downstream effectors such as CREB and other transcription factors. Moreover PKA is involved in the MAPK pathway where it interacts with proteins like MEK and ERK orchestrating responses to growth factors. These pathways demonstrate PKA’s role in integrating extracellular signals into cellular actions.
Dysregulation of PKA activity associates with conditions like Cushing's syndrome and cardiac hypertrophy. In Cushing's syndrome mutations affecting the regulatory subunit of PKA can lead to unregulated hormone activity. Cardiac hypertrophy involves altered PKA pathway signaling affecting heart muscle growth and function. PKA interacts with proteins such as phospholamban in cardiac disorders impacting calcium handling and heart contractility.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Titration of positive control (active PKA), background signal subtracted (duplicates; +/- SD).
Titration of cAMP Protein Kinase (Recombinant human cAMP Protein Kinase Catalytic subunit ab56268), background signal subtracted (duplicates; +/- SD).
1e7 3T3-L1 cells were treated for 15 minutes with 1 μM dexamethasone (Dexamethasone, anti-inflammatory glucocorticoid ab120743) and 1 μg/mL insulin (Recombinant human Insulin protein (Active) ab123768) with the addition of 50 μM forskolin (Forskolin, Adenylyl cyclase activator ab120058), 0.5 mM IBMX (IBMX, Non-specific cAMP and cGMP inhibitor ab120840) or 0.1 mM 8-CPT-cAMP (8-(4-Chlorophenylthio)adenosine 3',5'-cyclic monophosphate (8-CPT-cAMP), Cell permeable cAMP analog. ab120424). Cell extracts were prepared according to the protocol. Lysates were diluted 50-fold, and tested in duplicates (+/-SD).
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com